數位基因組設備市場：現況分析與預測（2023-2030）

由於慢性病盛行率不斷上升，數位基因組設備市場預計在預測期內將以 14% 的複合年增長率強勁增長。 例如，根據世界衛生組織 (WHO) 的數據，癌症是全球主要死亡原因之一，2020 年約有 1,000 萬人死於癌症，約佔死亡人數的六分之一。

依產品類型，市場分為序列及分析儀器、DNA/RNA 分析試劑盒、序列及分析軟體、樣品製備儀器等。 根據我們的分析，定序和分析設備領域將在 2022 年佔據主導份額。 定序和分析設備領域是數位基因組設備市場的重要組成部分。 此細分市場包括用於分析遺傳數據並識別 DNA 序列模式和突變的各種儀器，例如下一代定序儀 (NGS) 和桑格定序儀。 由於該領域存在各種儀器，因此序列和分析儀領域佔據了壓倒性的市場份額。

依應用劃分，市場分為微生物學、生殖/遺傳學、移植/農業和法醫學。 在預測期內，微生物學領域預計在數位基因組設備市場中將以更高的複合年增長率成長。 人類微生物組是生活在人體內的複雜微生物群落。 隨著科學家試圖了解微生物在人類健康和疾病中的作用，對微生物組的研究正在增加。 因此，對能夠分析微生物基因組的數位基因組儀器的需求不斷增長。

市場根據最終用戶細分為學術研究機構、診斷和法醫實驗室、醫院和生物製藥公司。 根據我們的分析，到2022年，醫院板塊將佔據主導份額。 先進技術的採用增加、對基因技術的需求不斷增加以及對更高效、更具成本效益的醫療保健的需求推動了醫院領域的成長。

為了更了解該產業的市場採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、義大利、西班牙、歐洲其他地區）、亞洲太平洋地區（根據世界其他地區（中國、日本、印度、韓國、澳洲和其他亞太地區）的全球影響力進行分析。 北美是醫療設備行業許多主要參與者的所在地，該地區高水準的醫療保健支出正在促進該地區數位基因組設備市場的成長。 此外，能夠快速識別疾病和感染的快速診斷測試在北美變得越來越流行。 數位基因組設備可用於開發此類測試，這推動了對這些設備的需求。

目錄

第 1 章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第 2 章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第 3 章市場總結

第 4 章執行摘要

第 5 章新型冠狀病毒感染（COVID-19）對全球數位基因組設備市場的影響

第 6 章 2020-2030 年全球數位基因組設備市場收入

第 7 章按產品類型劃分的市場洞察

• 定序與分析設備
• DNA/RNA 分析試劑盒
• 定序與分析軟體
• 樣品製備設備
• 其他

第 8 章按應用劃分的市場洞察

• 微生物學
• 繁殖和遺傳學
• 移植和農業
• 法醫學

第 9 章最終使用者的市場洞察

• 學術研究所
• 診斷與法醫實驗室
• 醫院
• 生物製藥公司

第 10 章按地區劃分的市場洞察

• 北美數位基因組設備市場
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲數位基因組設備市場
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區數位基因組設備市場
  • 中國
  • 日本
  • 印度
  • 韓國
  • 亞太地區的其他國家/地區
• 其他地區的數位基因組設備市場

第 11 章數位基因組設備市場動態

• 市場促進因素
• 市場挑戰
• 影響分析

第 12 章數位基因組設備市場機會

第 13 章數位基因組設備市場趨勢

第 14 章需求面與供給面分析

• 需求方分析
• 供給面分析

第 15 章價值鏈分析

第 16 章價格分析

第 17 章策略洞察

第 18 章競爭場景

• 競爭狀況
  • 波特五力分析

第 19 章公司簡介

• QIAGEN
• Thermo Fisher Scientific Inc.
• BD
• Agilent Technologies, Inc
• Illumina, Inc.
• PacBio
• BIOMERIEUX
• Genomic Health, Inc.
• PerkinElmer Inc
• Quest Diagnostics

第 20 章免責聲明

The Digital Genome Instrument (DGI) is a groundbreaking technology that allows for the rapid and accurate analysis of DNA samples. It is a portable device that can be used in remote locations or in the field, making it an ideal tool for researchers, doctors, and other professionals who need to quickly and efficiently collect and analyze DNA samples. The increasing prevalence of genetic disorders, along with the surging demand for personalized medicine is the major factor responsible for the growth of the digital genome instrument market. For instance, as per Medline Plus, about 1 in 200,000 people in the United States are diagnosed with syndrome A each year.

Digital Genome Instrument Market is expected to grow at a strong CAGR of 14% during the forecast period owing to the increasing prevalence of chronic diseases. For instance, as per the World Health Organization, cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Based on product type, the market is segmented into sequencing & analyzer instruments, DNA/RNA analysis kits, sequencing & analysis software, sample preparation instruments, and others. As per our analysis, the sequencing & analyzer instruments segment held a dominant share in 2022. The sequencing & analyzer instruments segment is a critical part of the digital genome instrument market. This segment includes a range of instruments such as next-generation sequencing (NGS) and Sanger sequencing instruments that are used to analyze genetic data and identify patterns and variations in DNA sequences. Due to the presence of a wide range of instruments in the segment, the sequencing & analyzer segment is witnessing dominating share of the market.

Based on the application, the market is segmented into microbiology, reproductive & genetic, transplantation & agriculture, and forensics. The microbiology segment is expected to grow with a higher CAGR in the digital genome instrument market during the forecast period. The human microbiome is a complex community of microorganisms that live on and inside the human body. Research into the microbiome is increasing, as scientists seek to understand the role of these microorganisms in human health and disease. This is driving the demand for digital genome instruments that can analyze microbial genomes.

Based on end-users, the market is segmented into academic research institutes, diagnostics & forensics labs, hospitals, and biopharmaceutical companies. As per our analysis, the hospital's segment held a dominant share in 2022. The growth of the hospital segment is being driven by the increasing adoption of advanced technology, the growing demand for genetic technology, and the need for more efficient and cost-effective healthcare.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America is home to a large number of leading players in the medical device industry, and the region has a high level of healthcare spending, which has contributed to the growth of the digital genome instrument Market in the region. Additionally, Rapid diagnostic tests are becoming increasingly popular in North America, as they allow for the rapid identification of diseases and infections. Digital genome instruments can be used to develop these tests, which is driving the demand for these instruments.

Some of the major players operating in the market include: QIAGEN; Thermo Fisher Scientific Inc.; BD; Agilent Technologies, Inc; Illumina, Inc.; PacBio; BIOMERIEUX; Genomic Health, Inc.; PerkinElmer Inc; and Quest Diagnostics.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Digital Genome Instrument Market
• 2.2. Research Methodology of the Digital Genome Instrument Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL DIGITAL GENOME INSTRUMENT MARKET COVID-19 IMPACT

6 GLOBAL DIGITAL GENOME INSTRUMENT MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Sequencing & Analyzer Instruments
• 7.2. DNA/RNA analysis kits
• 7.3. Sequencing & analysis software
• 7.4. Sample preparation instruments
• 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Microbiology
• 8.2. Reproductive & Genetic
• 8.3. Transplantation & Agriculture
• 8.4. Forensics

9 MARKET INSIGHTS BY END-USERS

• 9.1. Academic research institutes
• 9.2. Diagnostics & forensics labs
• 9.3. Hospitals
• 9.4. Biopharmaceutical companies

10 MARKET INSIGHTS BY REGION

• 10.1. North America Digital Genome Instrument Market
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe Digital Genome Instrument Market
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific Digital Genome Instrument Market
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. South Korea
  • 10.3.5. Rest of APAC
• 10.4. Rest of the World Digital Genome Instrument Market

11 DIGITAL GENOME INSTRUMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 DIGITAL GENOME INSTRUMENT MARKET OPPORTUNITIES

13 DIGITAL GENOME INSTRUMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. QIAGEN
• 19.2. Thermo Fisher Scientific Inc.
• 19.3. BD
• 19.4. Agilent Technologies, Inc
• 19.5. Illumina, Inc.
• 19.6. PacBio
• 19.7. BIOMERIEUX
• 19.8. Genomic Health, Inc.
• 19.9. PerkinElmer Inc
• 19.10. Quest Diagnostics

20 DISCLAIMER